Medegen said that it expects the value of the pharma contract manufacturing market to reach $8bn by the end of the year, with the requirement for such services to grow at an annual rate of 10 per cent. The company's Manufacturing Services unit will occupy the new 42,000-sq. ft site in Tijuana, where it will conduct "significantly expanded" manufacturing services for the medical device and pharmaceutical industries. The US Food and Drug Administration (FDA)-compliant facility will also handle the finished goods assembly for Medegen's in-house range of IV therapy products. "This marks a new milestone for Medegen as we focus on growing our medical Manufacturing Services business unit", said Jeff Goble, president of Medegen. According to Ross Magladry, Medegen's vice president of business development, Manufacturing Services, said that the coupling of its California-based medical device development resources, with the device assembly capabilities of the new Tijuana operation, allows Medegen to now offer a more comprehensive range of manufacturing services. "This expansion provides the market a one-stop alternative encompassing a scope of services from product design through sterile device distribution." The Mexico facility also provides clients with the opportunity for "cost-effective outsourcing solutions," added Goble.
